4 - 10 May 2019
These are links to news stories about multiple sclerosis from the last week that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Ocrevus approved for PPMS
The first disease modifying drug for people with primary progressive MS in England has been approved by NICE. Ocrevus (ocrelizumab) will be available for prescription for people with early, inflammatory primary progressive MS. Talks are underway about availability in the rest of the UK.
MS Trust link: Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS (includes the eligibility criteria for the drug)
Lack of services for people with advanced MS
David Martin of the MS Trust talks about the injustice of the two tier system for people with MS, where people who are eligible for a disease modifying drug are more likely to get a good service than those who aren't. He discussed the Advance MS Champions project that is trying to start to address this problem
MS Trust link: Advanced MS Champions
My search for MS support while studying for a PhD
4 Mar 2021 - 00:00
Laura is studying a PhD in Cancer Genomics and was diagnosed with MS in September 2020 following multiple hospital admissions. Here, Laura talks about how this affected her mental health and what more could be done to support other students going through the same thing.
MS, my mental health and a university degree
4 Mar 2021 - 00:00
Scarlet talks about how she learnt to manage her MS and mental health alongside the stresses of completing a university degree.
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.